Universidad Peruana Cayetano Heredia

Serum uric acid is associated with damage in patients with systemic lupus erythematosus

Mostrar el registro sencillo del ítem

dc.contributor.author Elera-Fitzcarrald, C.
dc.contributor.author Reátegui-Sokolova, C.
dc.contributor.author Gamboa-Cardenas, R.V.
dc.contributor.author Medina, M.
dc.contributor.author Zevallos, F.
dc.contributor.author Pimentel Quiroz, Víctor Roman
dc.contributor.author Cucho-Venegas, J.M.
dc.contributor.author Alfaro-Lozano, J.
dc.contributor.author Rodriguez-Bellido, Z.
dc.contributor.author Pastor-Asurza, C.A.
dc.contributor.author Perich-Campos, R.A.
dc.contributor.author Alarcón, Graciela S.
dc.contributor.author Ugarte Gil, Manuel Francisco
dc.date.accessioned 2020-07-14T00:01:09Z
dc.date.available 2020-07-14T00:01:09Z
dc.date.issued 2020
dc.identifier.uri https://hdl.handle.net/20.500.12866/8283
dc.description.abstract Introduction: Serum uric acid levels have been reported as predictors of cardiovascular, pulmonary, neurological and renal morbidity in patients with SLE. However, their role in cumulative global damage in these patients has not yet been determined. Objective: To determine whether serum uric acid levels are associated with new damage in patients with SLE. Methods: This is a longitudinal study of patients with SLE from the Almenara Lupus Cohort, which began in 2012. At each visit, demographic and clinical characteristics were evaluated, such as activity (Systemic Lupus Erythematosus Disease Activity Index-2K or SLEDAI-2K) and cumulative damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index or SDI). Treatment (glucocorticoids, immunosuppressive drugs and antimalarials) was also recorded. Univariable and multivariable Cox regression models were used to determine the impact of serum uric acid levels on the risk of new damage. Results: We evaluated 237 patients, with a mean age (SD) at diagnosis of 35.9 (13.1) years; 220 patients (92.8%) were women, and the duration of the disease was 7.3 (6.6) years. The mean SLEDAI-2K and SDI scores were 5.1 (4.2) and 0.9 (1.3), respectively. Serum uric acid level was 4.5 (1.4) mg/dL. Follow-up time was 3.1 (1.3) years, and 112 (47.3%) patients accrued damage during follow-up. In univariable and multivariable analyses, serum uric acid levels were associated with new damage (HR=1.141 (95% CI 1.016 to 1.282), p=0.026; HR=1.189 (95% CI 1.025 to 1.378), p=0.022, respectively). Conclusion: Higher serum uric acid levels are associated with global damage in patients with SLE. en_US
dc.language.iso eng
dc.publisher BMJ Publishing Group
dc.relation.ispartofseries Lupus Science and Medicine
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Article en_US
dc.subject cohort analysis en_US
dc.subject female en_US
dc.subject follow up en_US
dc.subject human en_US
dc.subject major clinical study en_US
dc.subject male en_US
dc.subject priority journal en_US
dc.subject risk factor en_US
dc.subject clinical feature en_US
dc.subject adult en_US
dc.subject demography en_US
dc.subject evaluation study en_US
dc.subject longitudinal study en_US
dc.subject antimalarial agent en_US
dc.subject disease activity score en_US
dc.subject disease duration en_US
dc.subject glucocorticoid en_US
dc.subject immunosuppressive agent en_US
dc.subject proportional hazards model en_US
dc.subject SLEDAI en_US
dc.subject systemic lupus erythematosus en_US
dc.subject uric acid blood level en_US
dc.title Serum uric acid is associated with damage in patients with systemic lupus erythematosus en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1136/lupus-2019-000366
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.01.03
dc.relation.issn 2053-8790


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas